Skip Navigation

Cardiovascular Research 2004 61(4):806-816; doi:10.1016/j.cardiores.2003.11.034
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Vilahur, G.
Right arrow Articles by Badimon, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vilahur, G.
Right arrow Articles by Badimon, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Inhibition of thrombosis by a novel platelet selective S-nitrosothiol compound without hemodynamic side effects*

Gemma Vilahura, María Isabel Baldelloua, Estefania Segalésa, Eduardo Salasb and Lina Badimon*,a

aCardiovascular Research Center, CSIC-ICCC, Hospital de la Santa Creu i Sant Pau (U.A.B.), Av. S. Antoni M. Claret 167, 08025 Barcelona, Spain
bLacer, S.A, Barcelona, Spain

* Corresponding author. Tel.: +34-934006146; fax: +34-932045904. lbmucv{at}cid.csic.es

Platelet and endothelial production of bioactive nitric oxide (NO) is known to be impaired in acute coronary syndromes, thus compounds that release NO are useful candidates to restore NO-vascular functions. Objective: We have studied whether donation of NO with a novel platelet-selective S-nitrosothiol compound (LA810) at a systemic level can inhibit thrombosis elicited by damaged vessel wall (eroded and disrupted vessel wall) at hemodynamic conditions typical of patent and stenotic coronary arteries. Methods: Thrombogenicity was measured in the porcine experimental model and assessed as platelet–thrombus formation in the ex vivo Badimon perfusion chamber. After baseline perfusions, female pigs (Large White x Landrace) were given intravenous infusion of LA810 or GSNO standard S-nitrosothiol during 2 h. Changes in blood pressure, heart rate and in vitro platelet aggregation were measured. Results: LA810 significantly decreased thrombus formation at any degree of vascular damage and shear rate (p<0.001) without hypotensive side-effects or heart rate variations. In contrast, inhibition of thrombus formation by GSNO required high doses associated to hypotensive episodes. Platelet aggregation induced by collagen was inhibited after nitrosothiol infusion in whole blood (LA810) and platelet rich plasma (LA810 and GSNO). In addition, there was a drug-dependent rise in platelet guanosine 3',5'-cyclic monophosphate (cGMP) levels. Conclusions: This new anti-ischemic NO-donor (NOd) LA810 that inhibits platelet function without hypotensive side-effects seems a highly efficacious strategy to reduce acute thrombosis triggered by coronary artery disease.

KEYWORDS Platelets; Nitric oxide; Thrombosis; Pig

Time for primary review 21 days

* This study was partially presented at the European Society of Cardiology 2002 receiving a Young Investigation Award.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.